SCHEMBL1945810

SCHEMBL1945810

CN(Cc1n[nH]c2c(=O)[nH]cnc12)C(CO)CO

nearest known ligand 0.64

Predicted protein targets (top 6)

geneUniProtsupporting neighboursconfidence
PNP P00491 18/20 0.64
KDM4A O75164 1/20 0.39
KDM4B O94953 1/20 0.39
KDM5C P41229 1/20 0.39
KDM5B Q9UGL1 1/20 0.39
PDPK1 O15530 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1947955 0.75 PNP (0.67) PNP
SCHEMBL1947954 0.75 PNP (0.67) PNP
SCHEMBL1948870 0.75 PNP (0.67) PNP
SCHEMBL18521204 0.74 PDPK1 (0.49) PNPKDM4AKDM4BKDM5CKDM5B
SCHEMBL1415736 0.74 PNP (0.62) PNP
SCHEMBL15315704 0.72 PNP (0.88) PNP
SCHEMBL15315710 0.72 PNP (0.88) PNP
SCHEMBL15315709 0.72 PNP (0.88) PNP
SCHEMBL670236 0.72 PDPK1 (0.46) PNPKDM4AKDM4BKDM5CKDM5B
SCHEMBL1415651 0.72 PNP (0.64) PNP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8853224-B2 Acyclic amine inhibitors of nucleoside phosphorylases and hydrolases INDUSTRIAL RESEARCH LIMITED (NZ) 2014-10-07 US claimed
US-20110130412-A1 Acyclic amine inhibitors of nucleoside phosphorylases and hydrolases BIOCRYST PHARMACEUTICALS, INC. 2011-06-02 US claimed
WO-2008030119-A9 ACYCLIC AMINE INHIBITORS OF NUCLEOSIDE PHOSPHORYLASES AND HYDROLASES INDUSTRIAL RESEARCH LIMITED (NZ) 2009-09-24 WO claimed
EP-2057165-A1 ACYCLIC AMINE INHIBITORS OF NUCLEOSIDE PHOSPHORYLASES AND HYDROLASES INDUSTRIAL RESEARCH LIMITED (NZ) 2009-05-13 EP claimed
WO-2008030119-A1 ACYCLIC AMINE INHIBITORS OF NUCLEOSIDE PHOSPHORYLASES AND HYDROLASES INDUSTRIAL RESEARCH LIMITED (NZ) 2008-03-13 WO claimed
US-10918641-B2 Use of MTAP inhibitors for the treatment of lung disease THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) 2021-02-16 US disclosed
US-20180353511-A1 Use of MTAP Inhibitors for the Treatment of Lung Disease ALBERT EINSTEIN COLLEGE OF MEDICINE, INC. 2018-12-13 US disclosed
WO-2017062421-A1 USE OF MTAP INHIBITORS FOR THE TREATMENT OF LUNG DISEASE THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) 2017-04-13 WO disclosed
US-8853224-B2 Acyclic amine inhibitors of nucleoside phosphorylases and hydrolases INDUSTRIAL RESEARCH LIMITED (NZ) 2014-10-07 US disclosed
EP-2395005-A1 Acyclic amine inhibitors of nucleoside phosphorylases and hydrolases Industrial Research Limited (NZ) 2011-12-14 EP disclosed
US-20110130412-A1 Acyclic amine inhibitors of nucleoside phosphorylases and hydrolases BIOCRYST PHARMACEUTICALS, INC. 2011-06-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180353511-A1 Use of MTAP Inhibitors for the Treatment of Lung Disease MTAP, TYMP, TPMT PNP 5/4885KDM4A 2672/4885KDM4B 3030/4885
US-20110130412-A1 Acyclic amine inhibitors of nucleoside phosphorylases and hydrolases PNP, TYMP, NTPCR PNP 1/4885KDM4A 2079/4885KDM4B 2095/4885
US-10918641-B2 Use of MTAP inhibitors for the treatment of lung disease MTAP, TYMP, TPMT PNP 5/4885KDM4A 2672/4885KDM4B 3030/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.